Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Trial Profile

Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2014

At a glance

  • Drugs EVP 0962 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors EnVivo Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top